Literature DB >> 30266585

Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.

Eunji Kim1, Hong-Gyun Wu2, Bhumsuk Keam3, Tae Min Kim3, Dong-Wan Kim3, Jin Chul Paeng4, Hak Jae Kim5, Ji Hyun Chang6.   

Abstract

PURPOSE: We analyzed positron emission tomography-computed tomography (PET-CT) in patients with stage III non-small-cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CRT) to examine the prognostic value of PET-CT parameters according to histologic subtypes (squamous cell carcinoma [SqCC] and adenocarcinoma [ADC]).
METHODS: A total of 130 patients with stage III NSCLC who underwent definitive CRT were identified. We obtained PET-CT parameters such as maximum (SUVmax) and mean (SUVmean) standardized uptake value, total lesion glycolysis (TLG), metabolic tumor volume (MTV), and coefficient of variation (CV). Each parameter was bifurcated based on the optimal cutoff, and propensity score matching was performed between the SqCC and ADC groups.
RESULTS: There were 108 patients with SqCC or ADC, and 44 patients each were allocated to the SqCC and ADC groups via propensity score matching. SUVmax, SUVmean, TLG, and MTV values were significantly higher in SqCC than in ADC (P = .004, P = .006, P = .003, and P = .03, respectively). In the SqCC group, PET-CT parameters were not associated with survival outcomes. However, in the ADC group, SUVmax and SUVmean were related to locoregional progression-free survival (P = .008 and P = .017, respectively), and TLG and MTV were related to overall survival (P = .044 and P < .001, respectively). In addition, patients with ADC showed more frequent distant metastasis (P = .011) and worse distant metastasis-free survival compared with patients with SqCC (P = .009).
CONCLUSIONS: PET-CT provided different prognostic implications between SqCC and ADC in patients with locally advanced NSCLC receiving radical CRT. This suggests that it is necessary to consider the histologic subtype and PET-CT parameters concurrently when predicting survival outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoradiation; Histology; Lung cancer; PET-CT; Prognostic factor

Mesh:

Substances:

Year:  2018        PMID: 30266585     DOI: 10.1016/j.cllc.2018.08.018

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

1.  Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.

Authors:  Olarn Roengvoraphoj; Lukas Käsmann; Chukwuka Eze; Julian Taugner; Arteda Gjika; Amanda Tufman; Indrawati Hadi; Minglun Li; Erik Mille; Kathrin Gennen; Claus Belka; Farkhad Manapov
Journal:  Transl Lung Cancer Res       Date:  2020-06

2.  Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration.

Authors:  Qing Peng; Li-Yuan Hao; Ying-Lin Guo; Zhi-Qin Zhang; Jing-Min Ji; Yu Xue; Yi-Wei Liu; Jun-Lan Lu; Cai-Ge Li; Xin-Li Shi
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

Review 3.  Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine.

Authors:  Haoyue Guo; Kandi Xu; Guangxin Duan; Ling Wen; Yayi He
Journal:  Ann Nucl Med       Date:  2021-11-02       Impact factor: 2.668

4.  Stage-Specific PET Radiomic Prediction Model for the Histological Subtype Classification of Non-Small-Cell Lung Cancer.

Authors:  Yanlei Ji; Qingtao Qiu; Jing Fu; Kai Cui; Xia Chen; Ligang Xing; Xiaorong Sun
Journal:  Cancer Manag Res       Date:  2021-01-12       Impact factor: 3.989

5.  Differential effect of GLUT1 overexpression on survival and tumor immune microenvironment of human papilloma virus type 16-positive and -negative cervical cancer.

Authors:  Byoung Hyuck Kim; Ji Hyun Chang
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.